The price reduction to the market, Changchun High -tech seems to be successful, and it has not fully succeeded

Northeast Medicine Mao Changchun High -tech, which has been "collected" countless times, is actually good.

On the evening of August 25, the semi -annual report disclosed by Changchun High -tech showed that the company's revenue in the first half of 2022 was 5.831 billion yuan, an increase of 17.5%year -on -year; net profit of home mother was 2.12 billion yuan, an increase of 10.21%year -on -year. Among them, the core subsidiary Jin Sai Pharmaceutical contributed more than 80 % of its performance.

The growth hormone of the golden race is still the biggest highlight. In the past five years, in addition to the short decline in the influence of the epidemic in 2020, the growth rate of growth hormone revenue has always remained at a high point, and it has remained above 50%for two consecutive years.

Now as long as the medicine that sells well, it can't hide the collection, as is the growth hormone. First, the Guangdong Alliance, and then the third batch of rumors of Zhejiang. On how Changchun High -tech explains, the market is unwilling to believe it. On the whole, the trend of Changchun High -tech stock price this year is not good.

Ji Cai did not hurt the company's performance significantly, but it triggered the crisis of trust in investors. This is the biggest problem that plagues Changchun High -tech.

Revenue reduction, but not because of the collection

The last time in Zhejiang's growth hormone collection may be a false alarm.

According to market rumors, Zhejiang Province released a "Third Batch of Pharmaceutical Pharmaceutical Purchasing Purchasing Documents (Draft for Soliciting Opinions)" in Zhejiang Province. Affected by this, Changchun High -tech stock price fell for 4 days in a row, and the agency sold at nearly 400 million yuan a day on the 18th.

This solicitation draft was later faked, but the stock price could be "seriously injured" by a collection of news that is difficult to distinguish between the market, which is exactly the cost of high dependence on a single variety.

In the first half of 2022, Golden Pharmaceutical achieved revenue of 4.963 billion yuan, accounting for 85%of the company's total revenue; net profit was 2.191 billion yuan, an increase of 17.86%year -on -year, and it still contributed its performance to Changchun High -tech. The 100 grams of biology, Hua Kang Pharmaceutical, China Academy of Pharmaceutical Enterprises, and three subsidiaries of high -tech real estate are still pulled up, and the total income brought about 10%of the total income.

Although the overall revenue number is beautiful, it can be seen when disassembled to each quarter.

In the second quarter, the revenue of Jin Sai Pharmaceuticals decreased by more than 1 billion yuan in the first quarter, and its net profit fell below 1 billion yuan. This has led to the growth rate of Changchun High -tech overall performance in the first half of this year. Compared with the past, the growth of revenue and net profit fell below 20%. Especially in the second quarter of a single quarter, revenue and net profit were only 2.856 billion yuan and 982 million yuan, respectively.

Changchun High -tech said that due to the control of the new crown epidemic, the company's overall new patients in the first half of the year increased smaller, and the Golden Pharmaceuticals even stopped production in April this year.

At a exchange meeting in June this year, Changchun Gaoxin was also frank, and the company's operation in Shanghai basically did not basically recover until the end of May.

Although the growth hormone has always been given consumer attributes, it depends on the doctor's prescription and recommendation. The suspension of medical institutions is almost deadly on the usage of related products, and this situation occurred in 2020.

In early August, Changchun High -tech emphasized at a conference call: The epidemic in 2021 was concentrated in the second half of the year, and the epidemic was greatly affected by the epidemic in the first half of this year. With the improvement of the epidemic, this situation will be improved accordingly. "In July, the overall situation of new affected groups and sales is good."

Price reduction promotion, long -term water needle volume is difficult

On the morning of August 26, Changchun High -tech stated at the institutional exchange meeting that long -term growth hormone "new patients accounted for steadily increased, and long -term growth hormone products revenue accounted for about 21%in the first half of the year."

Increasing the proportion of long -term water needles is the most wanted to do in Changchun High -tech.

At an investor exchange meeting in March this year, Changchun High -tech responded to the revenue composition of growth hormone products for the first time: the proportion of powder needles, water needles and long -term water needles was about 10%, 70%and 18%, respectively. The price of long -term water needles is the most expensive, and it is more convenient for patients. When the pink needle has been collected, it will push high -priced products, and Changchun High -tech ideas are well understood.

Because Changchun High -tech, Anke Bio and other mainstream companies abandoned the labels, the water needle "free" was "free" in the past, but the news of Zhejiang's virtual virtuality seems to show that the main sales of the water needle may eventually eventually will eventually eventually. The fate of difficult to escape the collection.

In order to promote the more expensive long -term water needles, it may also be for the unavoidable water acupuncture collection. Starting in March this year, Changchun High -tech has made the price of long -term water needles in each saving. The long -term water needle was reduced from the original 5,600 yuan to 3500 yuan, a decrease of 37.5%.

One of the main tasks of Changchun High-tech this year is to increase the promotion and assessment of long-term water needles. It is hoped that the proportion of long-acting water needles in 2022 will need to reach 25%-30%of the total product revenue.

It can maintain performance growth in the first half of the year, indicating that the strategy of Changchun High -tech "price reduction market" has been effective.

Judging from the current data, long -term water needles want to reach a 30%income ratio this year, Changchun High -tech still needs to work hard. According to information disclosed by the company, the proportion of long -term water needles revenue was as high as 25%in the first quarter, but the proportion of sales in the second quarter dropped.

If Changchun High -tech wants to achieve product replacement this year, he will have to work hard in the second half of the year.

####

- END -